Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy

被引:103
|
作者
Griggs, Jennifer J.
Culakova, Eva
Sorbero, Melony E. S.
van Ryn, Michelle
Poniewierski, Marek S.
Wolff, Debra A.
Crawford, Jeffrey
Dale, David C.
Lyman, Gary H.
机构
[1] Univ Rochester, Dept Med, Rochester, NY USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] RAND Corp, Pittsburgh, PA USA
[4] Duke Univ, Duke Comprehens Canc Ctr, Durham, NC 27710 USA
[5] Duke Univ, Dept Med, Durham, NC USA
关键词
D O I
10.1200/JCO.2006.08.3063
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The purpose of this study was to investigate the relationship between socioeconomic status (SES) and the use of intentionally reduced doses of chemotherapy in the adjuvant treatment of breast cancer. Patients and Methods Patients with breast cancer treated with a standard chemotherapy regimen (n = 764) were enrolled in a prospective registry after signing informed consent. Detailed information was collected on patient, disease, and treatment, including chemotherapy doses. Zip code level data on median household income, proportion of people living below the poverty level, and educational attainment were obtained from the US Census. Doses for the first cycle of chemotherapy lower than 85% of standard were considered to be reduced. Univariate analyses and multivariate logistic regression were performed to identify factors associated with the use of reduced first cycle doses. Results In univariate analysis, individual education attainment, zip code SES measures, body mass index, and geographic region were all significantly associated with receipt of intentionally reduced doses of chemotherapy. In multivariate analysis, controlling for geography, factors independently associated with reduced doses were obesity (odds ratio [OR], 2.47; 95% Cl, 1.36 to 4.51), severe obesity (OR, 4.04; 95% Cl, 1.46 to 11.19), and education less than high school (OR, 3.07; 95% Cl, 1.57 to 5.99). Conclusion Social disparities in breast cancer outcomes may be in part the result of lower quality chemotherapy doses in the adjuvant treatment of breast cancer. Efforts to address such prescribing patterns may help reduce SES disparities in breast cancer survival.
引用
收藏
页码:277 / 284
页数:8
相关论文
共 50 条
  • [1] Body mass index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer
    Kirsten A. Nyrop
    Jane Monaco
    Sanah Vohra
    Allison M. Deal
    William A. Wood
    Shlomit S. Shachar
    E. Claire Dees
    Gretchen G. Kimmick
    JoEllen C. Speca
    Hyman B. Muss
    [J]. Supportive Care in Cancer, 2023, 31
  • [2] Body mass index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer
    Nyrop, Kirsten A. A.
    Monaco, Jane
    Vohra, Sanah
    Deal, Allison M. M.
    Wood, William A. A.
    Shachar, Shlomit S. S.
    Dees, E. Claire
    Kimmick, Gretchen G. G.
    Speca, JoEllen C. C.
    Muss, Hyman B. B.
    [J]. SUPPORTIVE CARE IN CANCER, 2023, 31 (03)
  • [3] The effect of molecular subtype and body mass index on neo-adjuvant chemotherapy in breast cancer patients
    Iwase, Toshiaki
    Nakamura, Rikiya
    Yamamoto, Naohito
    Yoshi, Atushi
    Itami, Makiko
    Miyazaki, Masaru
    [J]. BREAST, 2014, 23 (03): : 264 - 272
  • [4] Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?
    Palleschi, Michela
    Scarpi, Emanuela
    Casadei, Chiara
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 255 - 256
  • [5] Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer
    Ricci, Marcos Desideio
    Formigoni, Maria Carolina
    Martins Zuliani, Lucia Maria
    Aoki, Denis Seiiti
    Mota, Bruna Salani
    Filassi, Jose Roberto
    Morales Piato, Jose Roberto
    Baracat, Edmund Chada
    [J]. REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2014, 36 (11): : 503 - 508
  • [6] Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?
    Michela Palleschi
    Emanuela Scarpi
    Chiara Casadei
    [J]. Breast Cancer Research and Treatment, 2021, 185 : 255 - 256
  • [7] Relationship of Body Mass Index with Prognosis in Breast Cancer Patients Treated with Adjuvant Radiotherapy and Chemotherapy
    Cihan, Yasemin Benderli
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (10) : 4233 - 4238
  • [8] SOCIOECONOMIC STATUS AND INFLAMMATION IN WOMEN WITH EARLY-STAGE BREAST CANCER: MEDIATION BY BODY MASS INDEX
    Pageot, Yrvane K.
    Stanton, Annette L.
    Ganz, Patricia A.
    Irwin, Michael R.
    Cole, Steve W.
    Crespi, Catherine M.
    Bower, Julienne E.
    [J]. PSYCHOSOMATIC MEDICINE, 2020, 82 (06) : A15 - A16
  • [9] Socioeconomic Status and Inflammation in Women with Early-stage Breast Cancer: Mediation by Body Mass Index
    Pageot, Yrvane K.
    Stanton, Annette L.
    Ganz, Patricia A.
    Irwin, Michael R.
    Cole, Steve W.
    Crespi, Catherine M.
    Breen, Elizabeth C.
    Kuhlman, Kate R.
    Bower, Julienne E.
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 2022, 99 : 307 - 316
  • [10] Effect of body mass index on chemotherapy-induced neutropenia in breast cancer.
    Yucel, Idris
    Teker, Fatih
    Kemal, Yasemin
    Ekinci, Ahmet Siyar
    Yilmaz, Bahiddin
    Kut, Engin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)